UCB’s growth driver squares up against the competition

UCB’s growth driver squares up against the competition

Source: 
EP Vantage
snippet: 

With data from a head-to-head trial against Cosentyx due soon, UCB’s bimekizumab seeks to enter a crowded psoriasis market.